• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

Medarex Announces Upcoming Presentations at American Association for Cancer Research Meeting

Posted on: Thursday, 14 April 2005, 06:00 CDT

PRINCETON, N.J., April 14 /PRNewswire-FirstCall/ -- Medarex, Inc. announced today that the following presentations on fully human antibodies derived from Medarex's UltiMAb(R) technology are expected to be presented or discussed at the 96th Annual Meeting of the American Association for Cancer Research (AACR) being held in Anaheim, CA on April 16-20, 2005.

Phase II MDX-010 Melanoma Data:

-- An oral presentation on "Autoimmunity correlates with tumor

regression in patients with metastatic melanoma treated with anti-

CTLA-4" (Abstract #6180) during the conference's Novel Vaccine and

Antibody Approaches mini-symposium on Wednesday, April 20th in Room

303C-D.

Preclinical MDX-1307 Data:

-- A poster presentation on "In vivo targeting of antigen leads

efficient antigen delivery and potent immune responses in human

mannose receptor transgenic mice" (Abstract #6046) during the

conference's Immunotherapy 3 poster session on Wednesday, April 20th

in Exhibit Hall B-D.

Other Preclinical Data:

-- A poster presentation on "Inhibition of IGF-1R signaling and tumor

cell proliferation by a fully human neutralizing anti-IGF-1R

antibody" (Abstract #5038) during the conference's Growth Factor

Receptors as Targets for Therapy poster session on Tuesday, April

19th in Exhibit Hall B-D; and

-- An oral presentation on "HGS-TR2J, an agonistic, TRAIL receptor 2

monoclonal antibody, actively and rapidly stimulates the TRAIL

receptor pathway that leads to significant inhibition of tumor growth

in human tumor cell lines in vitro and in vivo" (Abstract #4388)

during the conference's Cell Death Pathways, DNA Repair and Drug

Delivery mini-symposium on Tuesday, April 19th in Room 213.

Medarex is a biopharmaceutical company focused on the discovery and development of fully human antibody-based therapeutics to treat life- threatening and debilitating diseases, including cancer, inflammation, autoimmune disorders and infectious diseases. Medarex applies its UltiMAb(R) technology and product development and clinical manufacturing experience to generate, support and potentially commercialize a broad range of fully human antibody products for itself and its partners. Twenty-two of these therapeutic products derived from Medarex technology are currently in human clinical testing, with the most advanced product presently in a Phase III clinical trial. Medarex is committed to building value by developing a diverse pipeline of antibody products to address the world's unmet healthcare needs. For more information about Medarex, visit its website at http://www.medarex.com/.

Except for the historical information presented herein, matters discussed herein may constitute forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Statements that are not historical facts, including statements preceded by, followed by, or that include the words "potential;""believe;""anticipate;""intend;""plan;""expect;""estimate;""could;""may;" or similar statements are forward-looking statements. Medarex disclaims, however, any intent or obligation to update these forward-looking statements. Risks and uncertainties include risks associated with product discovery and development, uncertainties related to the outcome of clinical trials, slower than expected rates of patient recruitment, unforeseen safety issues resulting from the administration of treatment in patients, uncertainties related to product manufacturing as well as risks detailed from time to time in Medarex's public disclosure filings with the U.S. Securities and Exchange Commission (SEC), including its Annual Report on Form 10-K for the fiscal year ended December 31, 2004. There can be no assurance that such development efforts will succeed or that other developed products will receive required regulatory clearance or that, even if such regulatory clearance were received, such products would ultimately achieve commercial success. Copies of Medarex's public disclosure filings are available from its investor relations department.

Medarex(R), the Medarex logo and UltiMAb(R) are registered trademarks of Medarex, Inc. All rights are reserved.

Medarex, Inc.

CONTACT: Laura S. Choi, Investor Relations, +1-609-430-2880, x2216, orJean Mantuano, Corporate Communications (media), +1-609-430-2880, x2221, bothof Medarex

Web site: http://www.medarex.com/

Company News On-Call: http://www.prnewswire.com/comp/108265.html

Source: PRNewswire-FirstCall

More News in this Category